Last reviewed · How we verify
NCT04979000
HPV in Sinonasal Ca: Retrospective Analysis Association of Human Papilloma Virus (HPV) Serology and Behavioral Risk Factors
trial in Sinonasal Carcinoma in 49 participants. Completed in 28 May 2025.
28 May 2025
Quick facts
| Lead sponsor | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins |
|---|---|
| Status | Completed |
| Study type | OBSERVATIONAL |
| Enrollment | 49 |
| Start date | 3 August 2021 |
| Primary completion | 28 May 2025 |
| Estimated completion | 28 May 2025 |
| Sites | 1 location across United States |
Conditions studied
- Sinonasal Carcinoma — all drugs for Sinonasal Carcinoma →
- HPV-Related Squamous Cell Carcinoma — all drugs for HPV-Related Squamous Cell Carcinoma →
Sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins — full company profile →
Who can join
18 and older, any sex, with Sinonasal Carcinoma or HPV-Related Squamous Cell Carcinoma. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a case-control study designed to evaluate the role of anatomic site, gender and race in human papillomavirus-associated head and neck squamous cell cancers (HNSCC). We will explore the role of HPV, tobacco, alcohol and drug use, in HNSCC by tumor site with particular emphasis on the sinonasal cavity as well as differences in risk factors for HPV-positive HNSCC by gender and race.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Behavioral Risk Factors and Seroprevalence for Human Papillomavirus in Sinonasal Carcinoma: A Multi-Institutional Case-Control Study.
Tanavde V, Tharakan A, D'Souza G, Hachem RA, et al · · 2026 · PMID 41609014 · DOI 10.1002/hed.70171
Verify or expand the search:
- PubMed search for NCT04979000
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sinonasal Carcinoma
Currently open trials in the same condition.
- NCT07320508 — Epirubicin Interventional Chemotherapy for Sinonasal Adenoid Cystic Carcinoma (SNACC): A Prospective Study · Phase 2 · recruiting
Other Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins trials
Trials by the same sponsor.
- NCT07424222 — Ruxolitinib for Immune Effector Cell Associated Hemophagocytic Lymphohistiocytosis-like Syndrome (RISE) · Phase 1 · not yet recruiting
- NCT06210854 — Assessing Administration of pBI-11 Via Electroporation for the Treatment of Patients With HPV16/18+ · Phase 2 · not yet recruiting
- NCT07360119 — Total Pancreatectomy With Islet Autotransplantation (TPIAT) for High-Risk Patients With Pancreatic Tumors · NA · not yet recruiting
- NCT07140315 — DK222 Study at Hopkins · Phase 1 · recruiting
- NCT07071155 — Momelotinib in Combination With Hypomethylating Agent for Chronic Phase Myelodysplastic Syndromes/Myeloproliferative Ove · EARLY_PHASE1 · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04979000 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- Last refreshed: 22 September 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04979000.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing